We have an open position for a laboratory technician with focus on in vivo work (försöksdjurstekniker). Read more here or contact us directly for more information. We are welcoming applications until 10/10.
Recently, much attention has been given the role of proinflammatory cytokines in pathology of COVID-19. Massive release of cytokines, cytokine storm, is linked with disease severity in Acute Respiratory Distress Syndrome (ARDS), one of the major causes of death in COVID-19 patients. We are now offering a set of models, ranging from in vitro to in vivo models, for evaluation of acute innate immune responses. We have, in collaboration with Cellevate, developed a 3D human whole blood assay for in vitro testing. Our vivo model involves the same inflammatory triggers and allows evaluation of the systemic response. Contact us for quotes and more information or download the PDF describing the models below.
We are very happy to announce that our joint project application E!114520 ACTION has been approved as a Eurostars labelled project and funding by the EUREKA Association. The project consortium is focused on development of hormone analogue drugs for treatment of autoimmune diseases. The novel drug will target the endocrine-immune interphase and the strong relationship between the level of hormones and symptom severity of autoimmune diseases such as Rheumatoid Arthritis (RA). The goal of the project is to develop a modified hormone based drugs that selectively targets immune cells without interfering with reproductive hormones. Redoxis role in the project, with a total budget of 1,6 million Euros and duration of 36 months, will be focused on evaluation of the effects of the developed drug candidates in autoimmunity using our established preclinical model platform. By combining niched and specific competences of the consortium members we aim to deliver an IND approved drug ready for first-in-human trials post-project.
A warm welcome to Jens Holmberg, PhD, the latest addition to our team. Jens has a background in preclinical inflammation research with extensive experience in inflammatory in vivo and in vitro models. During his 15 years of post-PhD-experience at Biotech & Medtech companies, Jens has also experienced chief officer positions with focus on putting the company in a scientifically competitive position and to build company value. Jens will in his position as Scientific Director support our CRO team and also function as the project leader for Redoxis work in the Neutrocure program (H2020-FETOPEN) funded by the European union. We are very happy to have Jens aboard and are looking forward to some great research during the next years.